APA (7th ed.) Citation

W, Z., CF, G., JL, H., TY, L., YK, S., ZC, J., . . . AP, Z. (2025). Fruquintinib plus sintilimab in previously bevacizumab-treated, pMMR/MSS refractory metastatic colorectal cancer: A phase 2 clinical trial. Cancer immunology, immunotherapy : CII, 74(12), 381. https://doi.org/10.1007/s00262-025-04237-3

Chicago Style (17th ed.) Citation

W, Zhang, et al. "Fruquintinib Plus Sintilimab in Previously Bevacizumab-treated, PMMR/MSS Refractory Metastatic Colorectal Cancer: A Phase 2 Clinical Trial." Cancer Immunology, Immunotherapy : CII 74, no. 12 (2025): 381. https://doi.org/10.1007/s00262-025-04237-3.

MLA (9th ed.) Citation

W, Zhang, et al. "Fruquintinib Plus Sintilimab in Previously Bevacizumab-treated, PMMR/MSS Refractory Metastatic Colorectal Cancer: A Phase 2 Clinical Trial." Cancer Immunology, Immunotherapy : CII, vol. 74, no. 12, 2025, p. 381, https://doi.org/10.1007/s00262-025-04237-3.